HealthCare Global Enterprises Limited (HCG), a leader in cancer care, has partnered with Trucan Diagnostics Pvt Ltd, an innovative startup specializing in cancer diagnostics, to pioneer next-generation diagnostic tests aimed at improving cancer detection and treatment personalization. The collaboration will focus on validating advanced biomarker-driven tests developed by Trucan, which utilize next-generation sequencing to detect primary, recurrent, and metastatic cancers.
These tests are designed to predict therapy response before treatment and monitor patient progress during chemotherapy or targeted therapy. The data generated will support integration of these diagnostics into routine clinical practices, enhancing precision oncology capabilities. Dr. B.S. Ajaikumar, Executive Chairman of HCG, stated, “This partnership embodies our mission to innovate in cancer care.
Validating these diagnostics will empower oncologists with tools for personalized treatment planning, improving outcomes and quality of life for patients nationwide.” Dr. Raman Govindarajan, Founder of Trucan Diagnostics, added, “This collaboration is a crucial step toward advancing precision oncology and optimizing patient care.” In Kolkata, this innovation could transform oncology practices in eastern India, offering patients access to state-of-the-art diagnostics at lower costs. Leading oncologists in Kolkata view this as a promising step to address rising cancer cases with precision-driven treatments, benefiting both urban and rural patients.
